Webinar
Cost Comparison of Osimertinib + Chemo vs Amivantamab + Lazertinib in First-Line EGFR-Mutated NSCLC
Date: September 17, 2025 | 2:00 PM
The treatment landscape for EGFR-mutated NSCLC is shifting, with new regimens reshaping first-line care. Beyond clinical outcomes, cost considerations play a critical role in treatment decisions for both patients and payers.
This webinar takes a closer look at the economic impact of osimertinib + chemotherapy compared with amivantamab + lazertinib in patients with locally advanced or metastatic EGFRm NSCLC.
In this session, you will:
- A clear view of the 1L EGFRm NSCLC treatment landscape
- Insights into cost-of-care drivers: treatment acquisition, administration, healthcare resource use, and adverse event management
- Patient- and payer-level cost comparisons between FLAURA2 and MARIPOSA
Speakers:
Ultán McGlone, PharmD | University of Pittsburgh Medical Center
Jorge J. Nieva MD | Keck School of Medicine of USC & USC/Norris Cancer Center
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.